OptiBiotix Health PLC Technical, regulatory & commercial update (0749R)
September 19 2017 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 0749R
OptiBiotix Health PLC
19 September 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
SlimBiome(R): Technical, Regulatory and Commercial Update
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, provides the following technical, regulatory and
commercial update on its SlimBiome(R) product platform.
Technical Update
OptiBiotix has developed an improved version of SlimBiome(R)
using advanced processing technology which provides the following
benefits:-
i. Creating a single homogenous product reducing component
separation in transport and improving product consistency. This
opens up new application opportunities in areas which lack the
ability to blend or remix SlimBiome(R) (e.g. in store bakeries)
ii. Enhanced solubility giving better product presentation and
greatly enhancing flavour and mouthfeel. This improves the taste
and consumer experience of products containing SlimBiome(R) such as
'GoFigure(R)' shakes and bars
iii. Improved dispersion in water opening up new applications
areas to meets demand for 'on the go' products
iv. Lower manufacturing costs due to less waste and more efficient production processes
Commercial and Regulatory Update
OptiBiotix has made significant progress developing and
enhancing its pipeline of innovative products with a strong
scientific and clinical evidence base. This has attracted
commercial interest from a range of manufacturing, retail and
corporate partners. Recent commercial developments include:-
i. The Company has obtained FDA registration for both its
LP-LDL(R) and SlimBiome(R) product ranges allowing access to the US
market
ii. The Company will be launching its improved version of
SlimBiome(R) at Supply Side West and exhibiting with a potential
joint development partner, Cereal Ingredients Inc from Kansas, USA.
Cereal Ingredients is a privately held specialty ingredients
manufacturer, dedicated to the development and manufacture of
unique, high-quality products that contribute a meaningful point of
difference. Cereal Ingredients are looking to incorporate
SlimBiome(R) into their range of cereal based particulates and
ingredients, aimed at the nutraceutical, health and wellbeing
sectors of the industry.
Further product development is ongoing with a number of
manufacturers, corporates and large retailers to extend
SlimBiome(R)'s application into 'Health & Wellbeing' food and
beverage products. This is to coincide with increased consumer
awareness of using functional natural ingredients as part of a
healthy lifestyle to manage and reduce the risks of illness and
disease.
Stephen O'Hara, CEO of OptiBiotix, commented: "We have made
significant progress in our transition from a research and
development company to a commercial business, recently agreeing
deals with Tata, Sacco and Nutrilinea; companies with high industry
reputations and a global network of distribution partners. This
announcement updates investors on the technical and commercial
progress of our SlimBiome(R) product platform, building on its
proven science and consumer efficacy in GoFigure(R) products. As we
build the range of applications, products and geographic scope of
SlimBiome(R) with new manufacturing and distribution partners, the
scale of the opportunity enlarges allowing us to fully exploit the
revenue generating potential of our products. If successful, this
low risk, low cost approach to accessing multiple consumer
healthcare and pharmaceutical markets around the world with
multiple products has the potential to cumulatively generate
substantive revenues in the forthcoming years across all
platforms."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (Nomad) Tel: 020 7213
0880
Liam Murray
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876
741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDGGUWCBUPMGCR
(END) Dow Jones Newswires
September 19, 2017 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024